Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Appl Microbiol Biotechnol ; 57(5-6): 653-9, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11778874

ABSTRACT

A branching enzyme (EC 2.4.1.18) gene was isolated from an extremely thermophilic bacterium, Rhodothermus obamensis. The predicted protein encodes a polypeptide of 621 amino acids with a predicted molecular mass of 72 kDa. The deduced amino acid sequence shares 42-50% similarity to known bacterial branching enzyme sequences. Similar to the Bacillus branching enzymes, the predicted protein has a shorter N-terminal amino acid extension than that of the Escherichia coli branching enzyme. The deduced amino acid sequence does not appear to contain a signal sequence, suggesting that it is an intracellular enzyme. The R. obamensis branching enzyme was successfully expressed both in E. coli and a filamentous fungus, Aspergillus oryzae. The enzyme showed optimum catalytic activity at pH 6.0-6.5 and 65 degrees C. The enzyme was stable after 30 min at 80 degrees C and retained 50% of activity at 80 degrees C after 16 h. Branching activity of the enzyme was higher toward amylose than toward amylopectin. This is the first thermostable branching enzyme isolated from an extreme thermophile.


Subject(s)
1,4-alpha-Glucan Branching Enzyme/metabolism , Bacteria/enzymology , 1,4-alpha-Glucan Branching Enzyme/chemistry , 1,4-alpha-Glucan Branching Enzyme/genetics , Amino Acid Sequence , Aspergillus oryzae/enzymology , Aspergillus oryzae/genetics , Bacteria/genetics , Base Sequence , Cloning, Molecular , DNA, Bacterial/genetics , Enzyme Stability , Escherichia coli/enzymology , Escherichia coli/genetics , Genes, Bacterial , Hydrogen-Ion Concentration , Molecular Sequence Data , Molecular Weight , Phylogeny , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid
2.
Thromb Res ; 87(5): 447-59, 1997 Sep 01.
Article in English | MEDLINE | ID: mdl-9306619

ABSTRACT

An assay for the quantification of full-length and carboxy-terminus truncated tissue factor pathway inhibitor (TFPI) has been developed. The assay is a classical two-antibody sandwich assay with a monoclonal capture antibody directed against the third Kunitz-type domain of human TFPI and a polyclonal rabbit peroxidase-labelled anti-human TFPI detecting antibody. The assay is sensitive to full-length and carboxy-terminus truncated TFPI with intact third Kunitz-type domain, but not to two-domain TFPI. TFPI associated with lipoproteins is not or only sparsely detected and TFPI in complex with factor Xa only partially measured. The assays gives linear reference curves in the dose range of 5 to 100 ng/ml in a double logarithmic plot. The normal range assessed from analyses on citrated plasma from 81 normal human donors is 7.8 to 26.0 ng/ml (average +/- 2 SD, log-normal distribution). There is no statistically significant difference between TFPI levels measured in 10 fasting and 10 non-fasting individuals. The reproducibility of the assay is about 5.6-5.9% (relative standard error) and the within-days and between-day reproducibilities are 4.7-5.1% and 5.9-8.5%, respectively. The assay is in very good agreement with a commercial ELISA assay recently marketed. A robust, reproducible and convenient ELISA assay for the determination of full-length and three-domain TFPI has been developed.


Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Fibrinolytic Agents/blood , Lipoproteins/blood , Animals , Factor Xa Inhibitors , Humans , Rabbits , Reagent Kits, Diagnostic , Reference Values , Reproducibility of Results , Sensitivity and Specificity
3.
Thromb Haemost ; 66(4): 464-7, 1991 Oct 01.
Article in English | MEDLINE | ID: mdl-1796397

ABSTRACT

An increasing amount of evidence suggests that coagulation factors VIII and IX play a role not only in the intrinsic but also in the extrinsic pathway of coagulation. In this context the influence of the Extrinsic Pathway Inhibitor (EPI) on the coagulation time of hemophilia plasma lacking FVIII or FIX has been investigated. The coagulation time was measured in a dilute thromboplastin assay. Addition of recombinant EPI (rEPI) prolonged the coagulation time of normal plasma while the addition of an inhibitory antibody against EPI shortened the coagulation time. At low concentrations of thromboplastin the coagulation time of hemophilia plasma was prolonged and at all dilutions of thromboplastin, addition of anti-EPI IgG normalized the coagulation time of a hemophilia plasma. Analysis of 10 individual donor plasma samples and 8 individual hemophilia samples showed that addition of anti-EPI IgG shortened the coagulation time more in hemophilia plasma than in normal plasma. This illustrates the importance of a powerful extrinsic FVII dependent pathway to achieve hemostasis in the case of FVIII or FIX deficiency (hemophilia A and B).


Subject(s)
Blood Coagulation , Factor VII/antagonists & inhibitors , Hemophilia A/blood , Lipoproteins/antagonists & inhibitors , Protease Inhibitors/immunology , Thromboplastin/antagonists & inhibitors , Antibody Specificity/immunology , Factor VII/immunology , Humans , Immunoglobulin G/isolation & purification , Lipoproteins/immunology , Partial Thromboplastin Time , Reference Values , Thromboplastin/immunology , Time Factors
4.
Biochemistry ; 30(43): 10371-6, 1991 Oct 29.
Article in English | MEDLINE | ID: mdl-1931960

ABSTRACT

Tissue factor pathway inhibitor (TFPI) from different cell lines shows up to 15-fold differences in the ratio of anticoagulant to chromogenic activity. The anticoagulant activity was dependent on the purification procedure used and it was possible to isolate two fractions of recombinant TFPI. Only one of these fractions showed anticoagulant activity comparable with TFPI from normal human plasma, and Western blotting showed that the low-activity fraction did not react with an antibody raised against a peptide of TFPI located near the C-terminal. Analysis by mass spectroscopy of peptides from V8 protease digests showed that C-terminal amino acids could only be identified from the high-activity form, while heterologous fragmentation had taken place in the form with low anticoagulant activity. Previously published studies on TFPI have been performed using material of low anticoagulant activity compared with plasma TFPI, and we suggest that these studies have been performed with material degraded in the C-terminus.


Subject(s)
Anticoagulants , Factor VII/antagonists & inhibitors , Lipoproteins/metabolism , Thromboplastin/antagonists & inhibitors , Amino Acid Sequence , Animals , Blotting, Western , Cells, Cultured , Chromatography, Affinity , Cricetinae , Electrophoresis, Polyacrylamide Gel , Factor VII/metabolism , Factor VII/pharmacology , Humans , Kidney/cytology , Lipoproteins/pharmacology , Mass Spectrometry , Molecular Sequence Data , Peptide Mapping , Rabbits , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Thromboplastin/metabolism , Thromboplastin/pharmacology
5.
Thromb Res ; 62(6): 607-14, 1991 Jun 15.
Article in English | MEDLINE | ID: mdl-1926055

ABSTRACT

EPI released to the blood after injection of heparin, as well as recombinant EPI (r-EPI) added to normal plasma prolonged both the dilute Tissue Thromboplastin (TTP) time and the Activated Partial Thromboplastin Time (APTT). It is known that EPI inhibits both factor Xa and the factor VIIa-TTP complex. The prolongation of the APTT by EPI reflects only its inhibition of factor Xa. Addition of anti-EPI immunoglobulins (IgG) to normal plasma shortened the dilute TTP time 7.3 seconds (p less than 0.001) and the APTT by 0.7 seconds (p less than 0.001). In postheparin plasma, with polybrene added to neutralize the direct effect of heparin, the TTP was about 26 seconds longer and the APTT about 9 seconds longer than baseline values. These effects were completely abolished by anti-EPI IgG, as were the effects of r-EPI. The EPI activity (chromogenic substrate-assay) of this postheparin plasma was 1.7 U/ml. The EPI activity of the plasma spiked with r-EPI to obtain comparable effects on clotting were much higher; about 22 U/ml for the TTP effect and about 5 U/ml for the APTT effect. The findings indicate that r-EPI is considerably less potent than postheparin EPI as inhibitor of plasma coagulation. This is most striking when coagulation is initiated through the extrinsic pathway. Possibly, the anticoagulant effect of r-EPI mainly depends on its Xa inhibitory effect.


Subject(s)
Factor VII/antagonists & inhibitors , Factor Xa Inhibitors , Heparin/pharmacology , Lipoproteins/pharmacology , Recombinant Proteins/pharmacology , Thromboplastin/antagonists & inhibitors , Blood Coagulation Tests , Factor VII/metabolism , Factor VII/pharmacology , Factor VIIa/antagonists & inhibitors , Lipoproteins/metabolism , Partial Thromboplastin Time , Thromboplastin/metabolism , Thromboplastin/pharmacology
7.
Thromb Res Suppl ; 14: 39-48, 1991.
Article in English | MEDLINE | ID: mdl-1658969

ABSTRACT

It is known that the anticoagulant effect of blood or plasma is greater when heparin is given in vivo than when added in similar heparin concentrations in vitro. In this study, we neutralized heparin in citrated blood with polybrene, and then triggered coagulation with dilute tissue thromboplastin (TTP) and CaCl2. The clotting time was longer and the release of fibrinopeptide A (FPA) was retarded in the post injection samples compared to samples spiked with heparin in vitro. We have earlier reported that the extrinsic pathway inhibitor (EPI) is released to the blood after heparin injection. This was demonstrated here also for LMW heparin Enoxaparine both after intravenous and subcutaneous administration. Polyclonal blocking antibodies to EPI were added to blood or plasma heparinized in vivo or in vitro, and the direct heparin effect was neutralized with polybrene. When TTP and CaCl2 now were added and clotting time and the release of FPA recorded, the postheparin effect was greatly reduced by the antibodies. Addition of EPI antibodies to post-heparin plasma samples from cancer patients caused a marked reduction in the thromboplastin clotting times. We conclude that the release of EPI to the blood contributes significantly to the anticoagulant effect of heparin ex vivo.


Subject(s)
Blood Coagulation/drug effects , Factor VII/antagonists & inhibitors , Heparin/pharmacology , Lipoproteins/pharmacology , Thromboplastin/antagonists & inhibitors , Thromboplastin/pharmacology , Antibodies/immunology , Calcium Chloride/pharmacology , Factor VII/pharmacology , Fibrinopeptide A/analysis , Heparin Antagonists/pharmacology , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/pharmacology , Hexadimethrine Bromide/pharmacology , Humans , Injections, Intravenous , Injections, Subcutaneous , Lipoproteins/antagonists & inhibitors
8.
J Biol Chem ; 265(28): 16786-93, 1990 Oct 05.
Article in English | MEDLINE | ID: mdl-2211593

ABSTRACT

Previous studies have shown that extrinsic pathway inhibitor (EPI) is an effective inhibitor of factor Xa alone or factor VIIa-tissue factor complex in the presence of factor Xa. Since tissue factor exposure is implicated in thrombogenesis, we hypothesized that EPI may be valuable in the treatment of some thromboembolic episodes. Furthermore, EPI may be an important factor in bleeding complications in hemophiliacs. In the present study, human EPI was expressed in baby hamster kidney cells using a mammalian expression vector. Transfected cells expressed 1-2 micrograms/ml of recombinant EPI (rEPI) which was purified to homogeneity by heparin-Sepharose chromatography, ion-exchange chromatography, and reverse phase high performance liquid chromatography. Purified rEPI exhibited a specific activity of 30,000 units/mg and migrated as a single band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an apparent molecular weight of 42,000. In addition, the NH2-terminal sequence of rEPI was identical to that of HepG2 EPI and HeLa EPI. The ability of rEPI to inhibit factor X activation by a complex of factor VIIa-tissue factor was then examined in the presence and absence of plasma concentrations of human factors VIII and IX. Using relipidated human brain tissue factor apoprotein, rEPI inhibited the factor VIIa-mediated activation of factor X half-maximally at 2.5 and 1 nM in the presence and absence of factors VIII and IX, respectively. Using monolayers of a human bladder carcinoma cell line (J82) as the source of tissue factor, the activation of factor X by cell-bound factor VIIa was inhibited half-maximally by 5 nM rEPI in the presence of factors VIII and IX. The proteolytic activity of J82 cell-bound factor Xa toward prothrombin was inhibited half-maximally at approximately 5 nM rEPI, while the amidolytic activity of factor Xa in solution was inhibited by rEPI with a Ki of 130 pM. Recombinant EPI also inhibited the amidolytic activity of factor VIIa half-maximally at 10 nM rEPI in the presence of relipidated tissue factor apoprotein and calcium. These results indicate that, in the presence of plasma concentrations of factors VIII and IX, at least 10 times the plasma concentration of EPI is required to reduce factor VIIa-dependent factor X activation one order of magnitude in vitro. In the absence of functional factor VIII and IX, rEPI at plasma levels was a potent inhibitor of factor VIIa-mediated factor X activation, and this activity presumably accounts for the inability of hemophiliacs to initiate hemostasis via the extrinsic pathway.


Subject(s)
Blood Coagulation , Factor VII/antagonists & inhibitors , Lipoproteins/pharmacology , Thromboplastin/antagonists & inhibitors , Amino Acid Sequence , Antibodies , Base Sequence , Cell Line , Cloning, Molecular , Factor VII/genetics , Factor VII/isolation & purification , Factor VII/pharmacology , Factor VIIa/metabolism , Factor Xa/metabolism , Genetic Vectors , Humans , Kinetics , Lipoproteins/genetics , Lipoproteins/isolation & purification , Molecular Sequence Data , Molecular Weight , Oligonucleotide Probes , Peptides/chemical synthesis , Prothrombin/metabolism , RNA, Messenger/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , Thromboplastin/genetics , Thromboplastin/isolation & purification , Thromboplastin/pharmacology
9.
Exp Clin Endocrinol ; 93(2-3): 255-60, 1989 May.
Article in English | MEDLINE | ID: mdl-2550269

ABSTRACT

Pancreatic exocrine and ductal reacting monoclonal antibodies were derived from a mouse immunized with fixed pluripotent rat islet tumor cells (MSL) and boosted in vitro with fixed and concentrated tumor cell culture supernatant. Antibodies were obtained against duct cells, intercalated ducts, acinar cells and zymogen granules as well as against parietal cells. Unexpectedly, no monoclonal antibodies were directed against the endocrine pancreas, whereas six out of seven exocrine reacting antibodies stained total or subpopulations of cells in sections of monoclonal hypoglycemic MSL-tumors. These data may support the hypothesis of a common endodermal origin of the exocrine and endocrine pancreas.


Subject(s)
Adenoma, Islet Cell/immunology , Antibodies, Monoclonal , Pancreas/immunology , Pancreatic Neoplasms/immunology , Adenoma, Islet Cell/metabolism , Adenoma, Islet Cell/pathology , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Female , Immunohistochemistry , Mice , Mice, Inbred BALB C , Pancreas/cytology , Pancreas/metabolism , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...